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Abstract
Purpose Longitudinal studies in laryngeal cancer can provide clinicians information about short-term and long-term func-
tional outcomes, like quality of life (QoL) and voice outcome. This information is important when counseling patients or 
choosing a primary treatment modality. The present study assessed long-term (2 years) QoL and voice outcome in patients 
with extended T1 and limited T2 glottic carcinoma treated with transoral  CO2 laser microsurgery (TLM) (unilateral type III 
or bilateral type II resections).
Methods Three questionnaires were administered: the Voice Handicap Index (VHI), the European Organization for Research 
and Treatment of Cancer (EORTC) QoL questionnaire (QLQ)-C30, the EORTC QLQ-HN35. A perceptual voice evaluation 
at six different time points was conducted: preoperatively, and postoperatively at 6 weeks, 3 months, 6 months, 1 year, and 
2 years. Fluctuations over time were investigated.
Results Sixty-one patients were included in the analysis. Patients reported high-level functioning and low symptom scores 
2 years postoperatively. Gender significantly affected the VHI scores at 2 years (mean VHI scores: female 8.7 vs. male, 23.9; 
p = 0.023). The major improvement in VHI scores was observed within the first 6 months. The tumor stage (T1a, T1b, and T2) 
significantly impacted the grade (mean scores at 2 years: 1.0, 1.9, and 1.7; p = 0.001). These scores stabilized at 6 months.
Conclusions Patients show good long-term QoL with low symptom scores, a low voice handicap, and mild to moderate 
dysphonia, 2 years postoperatively. Scores stabilize at 6 months and provide a clear indication of status at 1 and 2 years.
Keywords Early glottic carcinoma · TLM · Laser surgery · Quality of life · Voice outcome · Questionnaire
Introduction
Early glottic carcinoma (Tis-T2) can be treated effectively 
with radiotherapy or transoral  CO2 laser microsurgery 
(TLM). According to the Dutch Guidelines for laryngeal 
carcinoma, TLM is the advocated treatment for superficial 
midcord T1a glottic carcinoma, and radiotherapy is indicated 
for more extended T1 and T2 glottic carcinomas [1]. Studies 
have shown that both therapies provided good, comparable 
oncological results [2–4], but some studies show superior 
laryngeal preservation after TLM [5–8]. There is less data 
on the functional outcomes of these treatment modalities, 
such as quality of life (QoL) and voice outcome, particularly 
in patients with T2 glottic carcinoma [7]. The lack of these 
data often prohibits adequate comparisons of modalities in 
patient counseling.
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Although oncological results play a highly significant 
role in selecting the treatment modality, functional out-
comes are also important when determining the patient’s 
treatment preferences. Each treatment modality has differ-
ent side effects, and patients may have different preferences 
regarding the trade-offs. Therefore, treatment decisions for 
early glottic carcinoma should be based on both oncologi-
cal and functional outcomes including patients’ preferences.
Several studies have investigated QoL in patients with 
early glottic carcinoma after treatment with radiotherapy or 
TLM [9–13]. Most have reported good postoperative QoL 
scores that were either the same or better than preoperative 
scores. A questionnaire that is often used and has a well-
proven method to measure QoL in cancer patients is the 
European Organization for Research and Treatment of Can-
cer (EORTC) QoL questionnaire (QLQ) C30, which is a 
general questionnaire. This can be complemented with the 
specific head and neck cancer module, the EORTC QLQ-
HN35. Both questionnaires ask the patient to rate their prob-
lems associated with their tumor and subsequent treatment 
and to reflect on their QoL. Voice outcome has also been 
studied in early glottic carcinoma after treatment with either 
radiotherapy or TLM. These studies showed that voice out-
come improved significantly postoperatively after the treat-
ment of Tis-T1a tumors (radiotherapy and TLM) or after 
limited resections (types I–II) (TLM) [12, 14, 15].
When the voice changes, it often affects patient’s self-per-
ception, as well as how others perceive their voice. Although 
many acoustic and aerodynamic parameters can be deter-
mined, these perceptive changes, such as dysphonia in the 
form of hoarseness or breathiness and an increase in vocal 
effort, are often the most fundamental to the patients and 
their surroundings. Therefore, measures of voice outcome 
that are often used in the clinical setting are self-assessment 
tools such as the Voice Handicap Index (VHI) and percep-
tual evaluation tools, such as the GRBAS rating scale.
Both QoL and voice outcomes may vary, mainly depend-
ing on the timing of the evaluation [16]. Most prospective 
studies have reported preoperative and 3- to 12-month post-
operative functional outcomes; in contrast, cross-sectional 
studies have only reported postoperative results, with large 
variations in time frames. The advantage of longitudinal 
studies is that they can assess changes over time and deter-
mine when a stable condition is achieved. This information 
can support clinicians in counseling patients about their 
long-term expectations, an essential component of a well-
informed treatment decision. In light of these findings, and 
due to the lack of long-term functional outcome data, the 
present study aimed to (1) assess long-term (2-year) results 
of QoL and voice outcome in patients treated with TLM for 
extended T1 and limited T2 glottic tumors and (2) investi-
gate fluctuations over time, based on prospectively collected 
data.
Methods and materials
Patients
From December 2009 to March 2015, this non-rand-
omized, prospective, longitudinal outcome study was 
conducted at the University Cancer Center, Leiden, The 
Hague, the Erasmus Medical Center, and The Netherlands 
Cancer Institute/Antoni van Leeuwenhoek Hospital in The 
Netherlands. Included patients were those with extended 
T1N0 and limited T2N0 glottic carcinomas, which would 
require a unilateral transmuscular resection [European 
Laryngological Society (ELS) classification [17] type III] 
or a bilateral subligamental resection (type II), if treated 
surgically. All patients with lesions that met these criteria 
were offered a treatment choice between TLM and radio-
therapy. Patients made their choice after comprehensive 
counseling (described elsewhere in detail by van Loon 
et al. [18]). After stroboscopy, the definite tumor stage 
was determined endoscopically under general anesthesia. 
Patients that met the inclusion criteria after endoscopy 
were enrolled in the study at that time. In case of T1b 
tumors, some procedures were staged to prevent web for-
mation. The QoL and voice outcome were assessed with 
patient self-report questionnaires and perceptual voice 
analyses conducted at various time points during follow-
up. The study was approved by the local Medical Ethics 
Committees at all three hospitals. Informed consent was 
obtained from all patients before inclusion into the study.
Questionnaires
We implemented three self-administered, validated ques-
tionnaires: the VHI-30 [19], the EORTC QLQ-C30 ver-
sion 3 [20], and the EORTC QLQ-HN35 [21]. Each was 
assessed at six different time points: preoperatively, and 
postoperatively, at 6 weeks, 3 months, 6 months, 1 year, 
and 2 years. Patients were asked to complete the question-
naires unaided during their visit to the outpatient clinic.
Voice Handicap Index
The Dutch version of the VHI is a validated 30-item ques-
tionnaire. It measures the psychosocial effects of voice 
impairments in daily life. Patients score each item by 
selecting a response from a five-point Likert scale, which 
ranges from 0 to 4 (0 = never, 4 = always). The sum of 
scores results in a total VHI score, which ranges from 0 
to 120. A higher score indicates a worse voice-related 
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outcome [19, 22]. A difference of ten points or more has 
been shown to be clinically relevant [23].
EORTC QLQ-C30
The EORTC-QLQ-C30 evaluates health-related QoL for the 
general population of patients with cancer. This question-
naire comprises 30 questions that address patient function 
and symptomatology over the preceding week. The question-
naire includes a global health status scale, five functional 
scales (physical, role, emotional, cognitive, and social), 
three multi-item symptom scales (fatigue, pain, and nausea 
and vomiting), and six single items that assess additional 
symptoms in patients with cancer (dyspnea, insomnia, appe-
tite loss, constipation, diarrhea, and financial difficulties). 
Patients score each item by selecting a response from a four-
point Likert scale from 1 (not at all) to 4 (very much), except 
for the global health status, which is scored from 1 (very 
poor) to 7 (excellent). These scores are transformed to a 
scale of 0–100. A higher score represents a higher (better) 
level of functioning or a higher (worse) level of symptoms 
[20]. A difference of ten points has been shown to be clini-
cally relevant [24, 25].
EORTC QLQ-HN35
The EORTC QLQ-HN35 evaluates health-related QoL for 
patients with head and neck cancer. It is often used to com-
plement the EORTC QLQ-C30. This questionnaire contains 
35 questions that address symptoms and side effects of treat-
ment, social function, and body image/sexuality. The ques-
tionnaire incorporates 7 multi-item scales: pain, swallowing, 
senses (taste and smell), speech, social eating, social contact, 
and sexuality; and 11 single items: teeth, opening mouth, dry 
mouth, sticky saliva, coughing, feeling ill, use of analge-
sics, nutritional supplements, feeding tube, weight loss, and 
weight gain. Each item is evaluated by selecting a response 
from a four-point Likert scale, the same as the scales used 
for the EORTC QLQ-C30. The final scores are transformed 
to a scale of 0–100. A higher score represents more severe 
problems or symptoms [21, 26]. A change of ten points has 
been shown to be clinically relevant [26].
Perceptual evaluation and voice recording
Perceptual evaluation was performed with the GRBAS 
rating scale on a 30-s running speech sample. Recordings 
were acquired at a sampling frequency of 44.1 kHz with 
a dual microphone headset recorder (Alphatron Medical 
Systems) and a Beyer dynamic microphone, in a noise-free 
environment. The speech sample consisted of a standard, 
phonetically balanced Dutch text, “80 dappere fietsers” [80 
brave cyclists]. The GRBAS rating scale consisted of five 
scales (grade, roughness, breathiness, asthenia, and strain), 
of which only the grade of dysphonia was rated because 
it reflects the overall degree of hoarseness or the severity 
of the voice abnormality [27]. Each sample was scored on 
a scale of 0 (normal voice) to 3 (severe dysphonic voice), 
and a higher score represented a more dysphonic voice 
[28]. A panel of four experienced listeners consisting of 
three speech–language pathologist and one ENT surgeon/
laryngologist, all specialized in both oncological and benign 
voice pathology and treatment (B.J.H., M.M.H., V.A.H. 
vdK., E.V.S.),and blinded to all data scored the grade of 
dysphonia. In those cases where the experts rated the voice 
differently, consensus was reached through re-evaluation of 
the speech sample and discussion. The interrater reliability 
of our experts was of 0.91 (95% CI 0.89–0.93).
Statistical methods
Statistical analyses were performed with SPSS version 23.0 
(IBM Corp, Armonk, NY, USA). Assumptions of normality 
were assessed. The effect of time on the different question-
naires was assessed with the linear mixed model analysis; 
the model was adjusted for four possible confounders: gen-
der, tumor stage, type of resection (unilateral type III vs. 
bilateral type II), and involvement of the anterior commis-
sure (AC; no involvement vs. unilateral or bilateral involve-
ment). Additionally, the least significant difference (LSD) 
post hoc test was used to adjust for multiple comparisons. 
The linear mixed model method was chosen, since it applies 
a correction for missing data. This correction is based on the 
observed data, and it uses all available information, without 
the need to censure an entire set of patient data, when one 
or more data points are missing or the need for imputation 
of measurements [29]. A p value of 0.05 was considered 
statistically significant.
Results
Patients
One hundred and seventy-five patients with suspected or 
proven extended T1 and limited T2 glottic tumors were iden-
tified as candidates for the study. Of these, 89 were suitable 
for inclusion, based on endoscopy. Of these, 13 patients were 
lost to follow-up or discontinued participation in the first 
3 months of the study. During the 2 years of follow-up, five 
patients died, due to unrelated causes, and ten patients devel-
oped recurrent disease. Thus, the final cohort comprised 61 
patients for analysis (Fig. 1). The baseline characteristics of 
these patients are presented in Table 1.
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Voice Handicap Index
The mean VHI score improved significantly over time, 
ranging from 30.5 preoperatively to 21.8 at 2 years (∆8.7, 
p = 0.003,). However, according to our definition, this 
improvement did not qualify as clinically relevant. The 
major improvement in the VHI score occurred within the 
first 6 months (∆7.2). Thereafter, only small additional 
improvements were noted between 6  months and the 
2-year follow-up. Gender was the only variable that sig-
nificantly affected the VHI score; the difference in mean 
VHI scores was 11.6 points (p = 0.023) between male 
and female patients. The difference in mean VHI score 
per time point between male and female patients was 7.8 
points (p = 0.204) preoperative, 14.6 points (p = 0.025) at 
6 weeks, 11.0 points (p = 0.090) at 3 months, 15.4 points 
at 6 months (p = 0.018), 5.9 points (p = 0.346) at 1 year, 
and 15.1 (p = 0.039) points at 2 years. At 2 years, females 
showed a lower (normalized) VHI score and a larger 
improvement (∆15.3) than males. Additionally, unlike the 
improvement observed in male patients, the improvement 
in the mean VHI score in female patients was clinically 
relevant (Table 2).
Total pa ents
175 
- discon nued par cipa on = 13
- developed recurrent glo c during 
follow-up = 10
- deceased = 5
Excluded pa ents
- Tis or midcord T1a tumor = 43
- unsuitable for laser treatment, due to 
difficult exposure = 9
- extended T2 tumor = 28
- other = 6
Analyzed pa ents
61
Assigned for the study
89
Fig. 1  Flow diagram of patient selection for the study
Table 1  Baseline characteristics
AC anterior commissure, ELS European Laryngological Society, SD 
standard deviation
Characteristics Number of 
patients (%)
Total = 61 
(100%)
Mean age at surgery, years (SD) 67.6 (8.90)
Gender
 Male 51 (83.6)
 Female 10 (16.4)
Tumor stage
 T1a 29 (47.5)
 T1b 19 (31.1)
 T2 13 (21.3)
Resection (ELS classification)
 Type III 38 (62.3)
 Type II bilateral 23 (37.7)
AC involvement
 No 12 (19.7)
 Unilateral 26 (42.6)
 Bilateral 23 (37.7)
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EORTC QLQ-C30
Patients showed good global health status preoperatively 
and the improvement in global health status over time was 
only borderline significant. It increased from 77 preop-
eratively to 81 at 2 years postoperatively (∆4, p = 0.047). 
However, this improvement did not qualify as clinically 
relevant. The results of the different functional scales 
showed that patients reported high levels of functioning. 
In all five scales, scores ranged from 88 to 97 points after 
2 years. One of these scales—the emotional function-
ing scale—showed a significant and clinically relevant 
improvement (∆18; p < 0.001), compared to preoperative 
values. The results of the symptom scales showed that 
patients also reported high levels of functioning on all 
items during the 2-year follow-up. The most common 
complaints were fatigue, dyspnea, and insomnia; scores 
ranged between 9 and 15 points. Only the change in insom-
nia showed a significant and clinically relevant improve-
ment compared to preoperative values (∆11; p < 0.025) 
(Table 3).
Table 2  Voice Handicap Index and perceptual evaluation results
∆difference between preoperative and the indicated follow-up time
Groups Preoperative
Mean
6 weeks
Mean (∆)
3 months
Mean (∆)
6 months
Mean (∆)
1 year
Mean (∆)
2 years
Mean (∆)
p value
Voice Handicap Index
 Overall (n = 61) 30.5 30.7 (0.23) 27.0 (− 3.5) 23.3 (− 7.2) 23.8 (− 6.7) 21.8 (− 8.7) 0.003
 Male (n = 51) 31.8 33.1 (1.3) 28.8 (− 3.0) 25.7 (− 6.0) 24.8 (− 6.9) 23.9 (− 7.9) < 0.001
 Female (n = 10) 24.0 18.5 (5.5) 17.8 (− 6.2) 10.4 (13.6) 18.9 (− 5.1) 8.7 (− 15.3) 0.111
Perceptual evaluation—grade
 Overall (n = 61) 1.5 1.9 (0.41) 1.6 (0.11) 1.4 (− 0.11) 1.3 (− 0.20) 1.4 (− 0.05) < 0.001
 T1a (n = 29) 1.3 1.6 (0.32) 1.2 (− 0.09) 1.1 (− 0.17) 1.1 (− 0.19) 1.0 (− 0.29) 0.027
 T1b (n = 19) 1.8 2.4 (0.69) 2.1 (0.34) 1.7 (− 0.08) 1.7 (− 0.03) 1.9 (− 0.15) 0.003
 T2 (n = 13) 1.7 1.9 (0.23) 1.8 (0.08) 1.6 (− 0.07) 1.3 (− 0.39) 1.7 (− 0.01) 0.198
 Male (n = 51) 1.5 2.0 (0.48) 1.6 (0.11) 1.4 (− 0.10) 1.4 (− 0.12) 1.5 (− 0.03) < 0.001
 Female (n = 10) 1.6 1.6 (0.01) 1.5 (− 0.12) 1.4 (− 0.22) 1.0 (− 0.58) 1.4 (− 0.25) 0.481
Table 3  Quality of life scores 
on the EORTC QLQ-C30 EORTC QLQ-C30 item PreoperativeMean
6 weeks
Mean
3 months
Mean
6 months
Mean
1-year
Mean
2-years
Mean
p value
Global health
Global health status 77 81 83 81 81 81 0.047
Functional scales
 Physical functioning 95 95 94 94 93 94 0.190
 Role functioning 95 96 94 94 95 97 0.635
 Emotional functioning 72 85 85 87 88 90 < 0.001
 Cognitive functioning 89 91 89 92 91 88 0.362
 Social functioning 92 93 95 96 95 95 0.402
Symptom scales
 Fatigue 20 15 14 15 17 12 0.118
 Nausea and vomiting 1 1 2 3 3 3 0.329
 Pain 6 7 3 4 7 5 0.173
 Dyspnea 17 15 18 20 19 15 0.509
 Insomnia 20 15 12 13 11 9 0.025
 Appetite loss 5 2 4 5 3 4 0.857
 Constipation 5 3 3 3 2 3 0.678
 Diarrhea 4 6 4 2 5 3 0.429
 Financial difficulties 6 4 3 3 2 3 0.262
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EORTC QLQ-HN35
The symptom scales showed low symptom scores at 2 years 
after treatment. As seen in the VHI questionnaire, gender 
had a significant effect on two items. Females had sig-
nificantly lower mean scores than males on speech prob-
lems (10.6 points difference; p = 0.037) and sticky saliva 
(11.8 points difference; p = 0.039). At 2 years postopera-
tively, most complaints were about speech problems (male 
patients), sexuality, sticky saliva (male patients), coughing, 
and the use of painkillers; the scores for these items ranged 
between 11 and 17 points. Nevertheless, compared to pre-
operative values, both speech problems (∆24, p < 0.001) and 
coughing (∆15, p = 0.002) showed significant and clinically 
relevant improvements at 2 years. Pain also showed a signifi-
cant improvement (∆4; p = 0.02), but this improvement did 
not qualify as clinically relevant. The improvement in speech 
problems among female patients was clinically relevant, but 
the change was not significant (∆13, p = 0.691) (Table 4).
Perceptual evaluation
The grade fluctuated significantly over time, and at 2 years, 
the pre- and postoperative values were similar (p < 0.001). 
Initial deterioration was observed at 6 weeks. Thereafter, 
recovery was noted, and the grade stabilized between the 
3- and 6-month time points. The tumor stage (T1a, T1b, 
and T2) had a significant impact on the grade (p = 0.001). 
Patients with T1a tumors had significantly better end scores 
than patients with T1b tumors (difference in means: 0.76, 
p < 0.001) and patients with T2 tumors (difference in means: 
0.49, p = 0.031). We found no significant difference between 
patients with T1b and T2 tumors (difference in means: 0.27, 
p = 0.256). At 2 years, the grade declined compared to pre-
operative values only in patients with T1a tumors (∆0.29; 
Table 2). Male and female patients did not have a mean 
difference in score (difference in means: 0.120, p = 0.644), 
although male patients fluctuated significantly over time 
(p < 0.001), whereas female patients did not (p = 0.481).
Discussion
This prospective study investigated QoL and voice out-
come for 2 years after TLM (unilateral type III resection 
or bilateral type II resection) in patients with early glot-
tic carcinoma (extended T1 and limited T2). Our results 
indicate good overall QoL with low symptom scores. The 
voice outcome data showed slightly elevated VHI and grade 
scores. The VHI showed most improvement within the first 
6 months. Interestingly, the VHI was significantly affected 
by gender; at 2 years after treatment, females showed scores 
Table 4  Quality of life scores 
on the EORTC QLQ-HN35
M male, F female
EORTC QLQ-HN35 item Preoperative
Mean
6 weeks
Mean
3 months
Mean
6 months
Mean
1 year
Mean
2 years
Mean
p value
Symptom scales
 Pain 8 5 5 6 6 4 0.029
 Swallowing 3 3 2 2 4 3 0.863
 Senses problems 5 5 3 4 5 4 0.855
 Speech problems (M) 38 31 20 18 13 14 < 0.001
 Speech problems (F) 20 15 10 10 10 7 0.691
 Trouble with social eating 2 2 2 2 2 2 0.970
 Trouble with social contact 4 4 2 3 4 4 0.269
 Less sexuality 14 15 17 15 18 17 0.905
 Teeth 9 3 9 8 6 8 0.329
 Opening mouth 3 2 2 2 5 2 0.220
 Dry mouth 18 13 17 19 15 9 0.079
 Sticky saliva (M) 15 16 12 10 15 13 0.363
 Sticky saliva (F) 0 4 0 5 4 0 0.963
 Coughing 28 21 21 22 16 13 0.002
 Felt ill 10 7 5 5 8 8 0.459
 Painkillers 13 8 10 7 12 11 0.333
 Nutritional supplements 1 2 1 0 4 0 0.169
 Feeding tube 0 0 0 1 0 0 0.451
 Weight loss 9 7 1 5 4 9 0.037
 Weight gain 5 19 19 23 17 7 < 0.001
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within the normal range (8.7 points) and males showed 
slightly elevated scores (23.9 points). The grade score for 
dysphonia declined initially after surgery and showed most 
of the improvement or recovery within the first 6 months. 
The grade was significantly affected, not by gender but by 
tumor stage. At 2 years, the grade scores were between 1.0 
(T1a) and 1.9 (T1b), which indicates mild (T1a) to moderate 
(T1b–T2) dysphonia. The final scores showed improvement 
for T1a tumors, but no change for T1b and T2 tumors, com-
pared to preoperative grade scores.
This study is one of the first to find a significant effect 
of gender on the VHI questionnaire, although we could not 
confirm this in the perceptual evaluation. Both men and 
women showed improvements over time, but only female 
patients achieved clinically relevant improvements. How-
ever, most likely due to the small sample size of female 
patients, this improvement did not reach statistical signifi-
cance. The female scores fluctuated over time, with an out-
lier score at 1 year. Therefore, in future studies with small 
groups, we recommend studying scores over time, rather 
than only evaluating two different time points. On the other 
hand, the improvement in male patients was statistically 
significant, but not clinically relevant. In contrast to these 
results, the study by van Gogh et al. reported no association 
between the VHI scores and gender, either in patients with 
voice impairments or in the population with normal glottic 
function [23]. However, in another study on patients with 
a variety of laryngeal diseases, Karlsen et al. found a cor-
relation (r = − 0.17, p < 0.05) between the VHI score and 
gender; female patients had lower scores than male patients 
[30]. This latter finding was consistent with our results, 
although no exact VHI scores were given in that study [30]. 
The difference in VHI improvement between males and 
females might be explained by the fact that women show 
postoperative fundamental frequencies within the normal 
female range, whereas male patients show postoperative fun-
damental frequencies that are higher than the normal male 
range (van Loon et al. [18]). Potentially, this characteristic 
could lead male patients to experience a larger change in 
their voice and therefore to be less satisfied. The potential 
impact of gender on voice outcome after TLM for glottic 
carcinoma must be confirmed in future studies in larger 
patient populations. Until then, these results should be inter-
preted with caution.
The finding that patients with T1a tumors had signifi-
cantly better grade scores than patients with T1b and T2 
tumors might be explained by the fact that a lower tumor 
stage requires a smaller volume resection of the vocal cords 
[31, 32]. During the first 6 weeks, a temporary deterioration 
in grade was observed for tumors in all stages, followed by 
an initial recovery at 3 months. Between the 3rd and 6th 
months, the grade further improved and stabilized. This pat-
tern was consistent with results reported in previous studies 
[33, 34]. At 2 years, only patients with T1a tumors showed 
significant improvements, compared to preoperative values.
After 6 months, only small changes in both the VHI 
and grade scores were observed. Therefore, improvements 
achieved at 6 months were indicative of the states achieved 
at 1 and 2 years postoperatively. Furthermore, the grade 
evaluations, showing mild to moderate dysphonia in both 
males and females, indicated that the voice did not return to 
normal levels after 2 years. This finding could be explained 
by the destructive effect of surgery on the vibratory layers of 
the vocal cord and the development of fibrosis. Interestingly 
however, the VHI did return to normal values for females 
and was only slightly elevated for males. This discrepancy 
between the VHI score and grade evaluation implies that 
there is a difference between what the patients experience 
and how experts rate their voices. This lack of correlation 
between the VHI questionnaire and the perceptual evalu-
ation has been shown in other studies [12, 14, 35, 36]. A 
study by van Loon et al. investigated the time trade off in 
patients with laryngeal cancer and concluded that none of 
the patients who were treated with TLM was prepared to 
trade off years to live in perfect health. This shows that the 
perceived side effects (e.g., dysphonia) by patients are not 
substantial and that patients are able to cope well with their 
limitations in daily life [37]. QoL is a multidimensional 
construct; thus, it is best measured with an instrument that 
reports on multiple domains of functionality and well-being. 
Among the most widely used questionnaires in head and 
neck cancer research are those developed by the EORTC 
(QLQ-C30 and QLQ-HN35). These questionnaires have 
been used in many studies on patients with laryngeal can-
cer. However, they have been used in only a few studies on 
patients with early glottic cancer [10, 12, 16, 38, 39]. Three 
of these studies compared QoL in patients with early glottic 
cancer that were treated with either radiotherapy or TLM 
[10, 38, 39]. Two previous studies focused exclusively on 
patients that underwent TLM [12, 16]. The study of Hsin 
et al. prospectively investigated 62 patients with early glottic 
cancer (Tis-T2) that underwent TLM (ELS types I–VI) [16]. 
They demonstrated an immediate decline in QoL scores in 
the first few months, which recovered to baseline after 6 
months, and then improved at 12 months, compared with 
preoperative scores. That finding is in contrast with findings 
in our study, because our patients did not report an immedi-
ate deterioration in QoL scores postoperatively. This differ-
ence might be explained by the fact that the previous study 
treated 15 patients (24%) with type IV–VI resections [16]; 
in contrast, we only treated patients with unilateral type III 
and bilateral type II resections.
Items on the QLQ-30 and QLQ-HN35 questionnaires 
have previously shown little differences in scores between 
men and women [40]. However, laryngeal cancer is less 
common in women than in men; thus, demonstrating 
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differences between the sexes can be challenging, due to the 
limited number of female patients. Several studies on either 
general populations or patients with laryngeal cancer have 
shown that women reported significantly worse QoL scores 
than men [41–44]. In our study, the data did not confirm 
this gender difference. On the contrary, we found that men 
reported significantly more problems of speech and sticky 
saliva than women did on the QLQ-HN35 items.
On both questionnaires (QLQ-C30 and QLQ-HN35), 
we observed slightly elevated values (12–17 points) for 
fatigue, dyspnea, speech (male patients), sticky saliva (male 
patients), coughing, and sexuality after 2 years of follow-up. 
Compared to normative data from the general Dutch popula-
tion, QLQ-C30 items (fatigue and dyspnea) that were less 
than 10 points different from the reference group [44] were 
not considered clinically relevant. In the literature, no study 
has reported normative data for the QLQ-HN35 question-
naire; therefore, the other slightly elevated items (speech 
problems, sticky saliva, coughing, and sexuality) could not 
be compared to a reference. One multinational study ana-
lyzed data on 293 patients with laryngeal cancer (stages 
I–IV). Although that study tested the reliability and validity 
of the head and neck cancer module, it did not report norma-
tive data. They included patients that were newly diagnosed, 
had recurrent disease or were disease free (1–3 years after 
treatment), and were primarily treated with radiotherapy 
[24]. Compared to those results, our patients reported fewer 
problems. This discrepancy might be explained by the fact 
that they included larger tumors than those we included, 
and their patients were treated primarily with radiotherapy. 
In the future, it would be interesting to generate normative 
data for the QLQ-HN35 module to enable comparisons with 
healthy individuals.
The strengths of this study is the prospective design and 
the duration of the follow-up. Due to the long-term follow-
up, we were able to show that the results at 6 months and 1 
year, which are more common time frames for these types 
of study, are representative for the long term. Our results 
have therefore been useful to us in counselling patients who 
undergo these specific resections on what to expect—both 
in terms of end results and the time frame within which 
these are achieved. The study had some limitations. First, 
due to the longitudinal nature of our study and the inclu-
sion of patients from three different hospitals, we could not 
avoid missing data, despite the prospective study design. In 
addition, we did not collect data on patient comorbidities 
and smoking after treatment. This could be of relevance and 
interesting for further research. Second, we did not collect 
data on speech therapy. However, all patients were instructed 
by the speech–language pathologist in vocal hygiene after 
TLM. No patient received speech therapy before 3 months 
after surgery. After that, speech therapy was administered on 
a case-by-case basis. We acknowledge that speech therapy 
can improve the voice results, and therefore we advocate 
the collection of data on speech therapy in future studies as 
suggested by Heijnen et al. [45]. Third, the sample size of 
female patients was small. Therefore, the significant effects 
of gender on the VHI and QLQ-HN35 questionnaire must be 
confirmed in future studies with lager sample size. Fourth, 
in the QLQ-HN35 we found a slightly elevated score in the 
item sticky saliva. Normally, you may expect elevated scores 
for sticky saliva after the treatment with radiotherapy and 
not after the treatment with TLM. However, no explanation 
could be given by the authors as to why sticky saliva showed 
elevated scores. Therefore, it would be interesting to gener-
ate normative data for this questionnaire.
Conclusion
Based on our findings, we conclude that patients with 
extended T1 and limited T2 tumors treated with TLM (uni-
lateral type III or bilateral type II) show good QoL with 
low symptom scores and slightly elevated voice outcome 
data, at 2 years after treatment. Most of the improvement 
is observed within 6 months, and this level of improvement 
provides a clear indication of the status at 1 and 2 years post-
operatively. These findings are useful for guiding patients in 
clinical decision making.
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